Search Result
Results for "
Hepatocytes
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
7
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-132600A
-
|
Temavirsen sodium
|
MicroRNA
HCV
|
Infection
|
|
RG-101 sodium is a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that antagonises miR-122. miR-122 is an important host factor for hepatitis C virus (HCV) replication .
|
-
-
- HY-W018392
-
|
MEHP; Phthalic acid mono-2-ethylhexyl ester
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-N7133
-
|
N-Phenylaniline hydrochloride
|
Fungal
Bacterial
|
Others
|
|
Diphenylamine is a common structure of nonsteroidal anti-inflammatory drugs (NSAIDs) to uncouple mitochondrial oxidative phosphorylation and to cause a decrease in hepatocellular ATP content and hepatocyte injury. Diphenylamine is used as an industrial antioxidant, dye mordant and is also applied in agriculture as a fungicide and antihelmintic .
|
-
-
- HY-149392
-
|
|
HBV
|
Infection
|
|
HBV-IN-35 (Compound 88) is a HBV inhibitor. HBV-IN-35 has anti-HBV activities in mouse and human hepatocytes (EC50: 100 nM and 400 nM respectively) .
|
-
-
- HY-132600
-
|
Temavirsen
|
MicroRNA
HCV
|
Infection
|
|
RG-101 is a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that antagonises miR-122. miR-122 is an important host factor for hepatitis C virus (HCV) replication .
|
-
-
- HY-114611
-
|
|
IRE1
|
Metabolic Disease
|
|
BDM44768 is an inhibitior of IDE. BDM44768 exacerbates ER stress-induced IRE1 activation and promotes lipid accumulation in hepatocytes. BDM44768 potentiates activation of the IRE1 pathway in the liver and exacerbates liver lipid accumulation in an acute mice model of ER stress .
|
-
-
- HY-N2140
-
|
|
Others
|
Infection
|
|
Herpetone, the ethylacetate extract, is a lignan compound. Herpetone can be isolated from the seeds of Herpetospermum caudigerum. Herpetone significantly improved the cell viability, and has a protective effect on hepatocytes in vitro .
|
-
-
- HY-108614
-
|
|
Others
|
Metabolic Disease
|
|
GPi688 is a potent and orally active glycogen phosphorylase (GPa) inhibitor with IC50s of 19 nM, 61 nM and 12 nM for human liver GPa, rat liver GPa and human skeletal muscle GPa, respectively . GPi688 can inhibit glucagons-mediated glucose output in rat primary hepatocytes. GPi688 can be used for researching glucagon-mediated hyperglycaemia .
|
-
-
- HY-110134
-
|
|
Constitutive Androstane Receptor
|
Metabolic Disease
|
|
S07662 is a human constitutive androstane receptor (hCAR) inhibitor with an IC50 of 0.7 μM. S07662 recruits the corepressor NCoR in cell-based assays and attenuate the expression of CYP2B6 mRNA in human primary hepatocytes induced by phenytoin (HY-B0448) and CITCO (HY-103244) .
|
-
-
- HY-W018392S
-
|
MEHP-d4; Phthalic acid mono-2-ethylhexyl ester-d4
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
|
Mono-(2-ethylhexyl) phthalate-d4 is a deuterium labeled Mono-(2-ethylhexyl) phthalate (HY-W018392). Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-W018392R
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Mono-(2-ethylhexyl) phthalate (Standard) is the analytical standard of Mono-(2-ethylhexyl) phthalate. This product is intended for research and analytical applications. Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-147645
-
|
|
FBPase
|
Metabolic Disease
|
|
FBPase-IN-2 (HS36) is a potent Fructose-1,6-bisphosphatase (FBPase) covalent inhibitor with an IC50 of 0.15 μM. FBPase-IN-2 reduces glucose production in hepatocytes. FBPase-IN-2 can be used for type 2 diabetes mellitus research .
|
-
-
- HY-W176012
-
|
|
Others
|
Metabolic Disease
|
|
Glycolate oxidase-IN-1(compound 26), a salicylic acid derivative, is a glycolate oxidase (GO) inhibitor with an IC50 of 38.2 μM. Glycolate oxidase-IN-1 has the ability to reduce oxalate production in hyperoxalate hepatocytes and can be used in the study of primary hyperoxaluria type 1 (PH1) .
|
-
-
- HY-137397
-
|
8-OH-EFV
|
Apoptosis
JNK
|
Cancer
|
|
8-Hydroxyefavirenz (8-OH-EFV) is a primary metabolite of (HY-10572). 8-Hydroxyefavirenz induces apoptosis via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. 8-Hydroxyefavirenz can be used in research of cancer . 8-Hydroxyefavirenz is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-108469
-
BI-6015
3 Publications Verification
|
Others
|
Metabolic Disease
Cancer
|
|
BI-6015 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BI6015 represses insulin promoter activity through HNF4α antagonism. BI-6015 can be used for the research of cancer and diabetes .
|
-
-
- HY-P99217
-
|
AMG 102
|
c-Met/HGFR
|
Cancer
|
|
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
|
-
-
- HY-106961
-
|
ONO-AP 500-02
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
|
-
-
- HY-P99196
-
|
|
c-Met/HGFR
|
Cancer
|
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
|
-
-
- HY-13529
-
|
LY2608204
|
Glucokinase
|
Metabolic Disease
|
|
Globalagliatin (LY2608204) is an orally active glucokinase (GK) activator with an EC50 of 42 nM. Globalagliatin also stimulates glucose metabolism in rat insulinoma INS1-E cells with EC50 of 579 nM. Globalagliatin targets both pancreatic β-cells and hepatocytes. Globalagliatin is promising for research of type 2 diabetes .
|
-
-
- HY-144341
-
|
|
Bacterial
|
Infection
|
|
DprE1-IN-1 is a potent, orally active DprE1 inhibitor with favorable hepatocyte stability, low cytotoxicity and low hERG channel inhibition. DprE1-IN-1 displays potent activity against both agent-susceptible and clinically isolated drug-resistant Tuberculosis strains with MICs10 CFU reduction in macrophages.
|
-
-
- HY-B0822
-
|
|
GABA Receptor
Cytochrome P450
Apoptosis
|
Neurological Disease
|
|
Fipronil is a broad-spectrum insecticide effective against Lepidoptera species as well as thrips, locusts, ants, cockroaches, fleas and ticks. Fipronil selectively inhibits GABA receptor with IC50s of 30 nM and 1600 nM for cockroach and rat GABA receptors, respectively. Glutamate-gated chloride channels (GluCls), which are present in cockroaches but not in mammals, are sensitive to the blocking effect of Fipronil. Fipronil also induces apoptosis in HepG2 cells and promotes the expression of CYP1A1 and CYP3A4 mRNA in human hepatocytes .
|
-
-
- HY-117985
-
|
DA-1229
|
Dipeptidyl Peptidase
Autophagy
|
Metabolic Disease
Inflammation/Immunology
|
|
Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
|
-
-
- HY-106961A
-
|
(Z)-ONO-AP 500-02
|
Others
|
Cardiovascular Disease
|
|
(Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
|
-
-
- HY-12346
-
|
NSC 12407; BRD-K4477
|
Others
|
Others
|
|
FH1 (NSC 12407) enhances hepatocyte functions, and promotes the differentiation of induced pluripotent stem (iPS)-derived hepatocytes toward a phenotype more mature and the maturation of well-differentiated cultures of hepatocyte-like cells (iHeps) .
|
-
-
- HY-117985B
-
|
DA-1229 tartrate
|
Dipeptidyl Peptidase
Autophagy
|
Metabolic Disease
Inflammation/Immunology
|
|
Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
|
-
-
- HY-12784AS
-
|
|
Parasite
Drug Metabolite
|
Infection
|
|
Cycloguanil-d4 (hydrochloride) is the deuterium labeled Cycloguanil hydrochloride. Cycloguanil hydrochloride, the active metabolite of Proguanil, acts on malaria schizonts in erythrocytes and hepatocytes[1].
|
-
-
- HY-155354
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 33 (compound 5g) has antiplasmodial activity against erythrocytic and hepatic stages of Plasmodium with an EC50 of 1.1 μM for K1 P. falciparum strain. Antimalarial agent 33 demonstrats enhanced microsomal stability (T1/2=29 min). Antimalarial agent 33 has no significant cytotoxicity against primary hepatocytes .
|
-
-
- HY-124364
-
|
|
HBV
Cytochrome P450
|
Infection
Metabolic Disease
|
|
RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation .
|
-
-
- HY-157088
-
|
|
Caspase
Apoptosis
Cyclophilin
|
Others
|
|
C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC 50 of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model .
|
-
-
- HY-132604
-
|
ARO-AAT
|
Small Interfering RNA (siRNA)
|
Metabolic Disease
|
|
Fazirsiran (ARO-AAT) is a second-generation RNAi agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
|
-
-
- HY-132604A
-
|
ARO-AAT sodium
|
Small Interfering RNA (siRNA)
|
Metabolic Disease
|
|
Fazirsiran sodium is a second-generation RNAi agent. Fazirsiran sodium consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran sodium can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
|
-
-
- HY-12784
-
-
-
- HY-12784A
-
-
-
- HY-B2119
-
|
Tauroglycocholic acid sodium salt
|
Biochemical Assay Reagents
|
Endocrinology
|
|
Sodium tauroglycocholate is an inhibitor of the biliary acid transporting system of the hepatocyte and also a surfactant used as a chemical permeation enhancer.
|
-
-
- HY-12281
-
|
BRD-9424
|
Others
|
Metabolic Disease
Cancer
|
|
FPH2 induces of functional proliferation of primary human hepatocytes and may lead to the development of new therapeutics for liver diseases.
|
-
-
- HY-126225
-
|
|
Others
|
Metabolic Disease
|
|
SJA710-6 is a small molecule able to selectively differentiate MSCs toward hepatocyte-like cells .
|
-
-
- HY-N8141
-
|
|
Others
|
Metabolic Disease
|
|
Regaloside H, a phenylpropanoid glycerol glucoside, is a gluconeogenesis inhibitor. Regaloside H can reduce glucose production in Hepatocytes .
|
-
-
- HY-132814
-
-
-
- HY-137455
-
-
-
- HY-12784AS1
-
-
-
- HY-139735
-
|
|
Others
|
Cancer
|
|
Antitumor agent-29 is a novel hepatocyte-targeting antitumor proagent, which exhibits good antitumor activity and low toxic side effects.
|
-
-
- HY-N7790
-
|
|
Others
|
Cancer
|
|
Citrusinol is a natural product isolated from D. caudatum. Citrusinol has anticancer activity and inhibits the proliferation and migration of human hepatocytes HepG 2 .
|
-
-
- HY-P10241
-
|
|
Apoptosis
Caspase
|
Cancer
|
|
Ac-LEHD-CHO is an inhibitor for caspase 8/9. Ac-LEHD-CHO prevents GalN/TNF-α-induced hepatotoxicity and hepatocyte apoptosis .
|
-
-
- HY-106379
-
|
GR-87442
|
5-HT Receptor
|
Neurological Disease
|
|
Lurosetron (GR-87442) is a 6-fluoro analogue of Alosetron (HY-70050A). Lurosetron is a serotonin 5-HT3 receptor antagonist. Lurosetron inhibits recombinant (rbt) CYP1A2, with an IC50 of 0.1 μM. Lurosetron also inhibits other CYP isoforms, including rbtCYP2C9 and rbtCYP3A4 with IC50s ranging between 3.5 μM and 16 μM. .
|
-
-
- HY-125731
-
-
-
- HY-N10426
-
|
|
Glucosidase
|
Metabolic Disease
|
|
(+)-Cembrene A (Compound 5) is a α-glucosidase inhibitor with an IC50 of 30.31 μM. (+)-Cembrene A is nontoxic towards human normal hepatocyte (LO2) cells .
|
-
-
- HY-N6638
-
|
|
Others
|
Metabolic Disease
|
|
Retrorsine is a naturally occurring toxic pyrrolizidine alkaloid. Retrorsine can bind with DNA and inhibits the proliferative capacity of hepatocytes. Retrorsine can be used for the research of hepatocellular injury .
|
-
-
- HY-100590
-
|
BRD6125
|
Others
|
Others
|
|
FPH1(BRD-6125) increases the number and activity of primary human hepatocytes in vitro and promotes the differentiation of iPS cells towards a hepatic lineage .
|
-
-
- HY-112540B
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Acetoacetic acid sodium is a metabolite of non-esterified fatty acids, involved in the development of human diabetes. Acetoacetic acid sodium induces oxidative stress to inhibit the assembly of very low density lipoprotein in bovine hepatocytes .
|
-
-
- HY-156897
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-amide-Ph-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs) .
|
-
- HY-N12719
-
|
|
Others
|
Others
|
|
Isocampneoside I is an acylated phenethyl oligosaccharide that can be isolated from Cistanche deserticola (Orobanchaceae). Isocampneoside I inhibits D-galactose-induced cytotoxicity and protects primary hepatocytes in mice .
|
-
- HY-115319
-
|
|
Ferroptosis
|
Inflammation/Immunology
|
|
CP-24879 (hydrochloride) is a potent, selective and combined delta5D/delta6D inhibitor. CP-24879 (hydrochloride) can significantly reduce intracellular lipid accumulation and inflammatory injury in hepatocytes. CP-24879 (hydrochloride) exhibits superior antisteatotic and anti-inflammatory actions in fat-1 and ω-3-treated hepatocytes, and can be used for non-alcoholic steatohepatitis research .
|
-
- HY-115853
-
|
|
Others
|
Others
|
|
Pyclen is a compound used for liver-specific MRI. Related compounds were synthesized as ligands of manganese (II) and have certain relaxivity and hepatocyte uptake ability. It is a potential liver-specific contrast agent.
|
-
- HY-12423
-
|
TAS-115
|
VEGFR
c-Met/HGFR
|
Cancer
|
|
Pamufetinib (TAS-115) is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
|
-
- HY-12423A
-
|
TAS-115 mesylate
|
VEGFR
c-Met/HGFR
|
Cancer
|
|
Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
|
-
- HY-N4323
-
|
|
Calcium Channel
|
Neurological Disease
Metabolic Disease
|
|
14-Deoxyandrographolide is a labdane diterpene with calcium channel blocking activity. 14-Deoxyandrographolide desensitizes hepatocytes to TNF-α-mediated apoptosis through the release of TNFRSF1A release .
|
-
- HY-P1415
-
-
- HY-156896
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Val-Cit-amide-Cbz-N(Me)-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs) .
|
-
- HY-115449
-
|
94G6
|
IGF-1R
Akt
mTOR
|
Cancer
|
|
Chromeceptin (94G6) is an IGF signaling pathway inhibitor. Chromeceptin suppresses IGF2 expression at mRNA and protein levels in hepatocyte and HCC cells. Chromeceptin inhibits the phosphorylation levels of AKT and mTOR .
|
-
- HY-156683
-
|
|
Lactate Dehydrogenase
|
Metabolic Disease
|
|
CHK-336 (Example 1) is an orally active LDHA inhibitor (IC50<1 nM) that inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria .
|
-
- HY-129315
-
|
N-Deacetylketoconazole; R-39519
|
Bacterial
Fungal
|
Infection
|
|
Deacylketoconazole (N-Deacetylketoconazole; R-39519) is an orally active metabolite of Ketoconazole (HY-B0105). Deacylketoconazole exhibits antifungal and antibacterial activity. Deacylketoconazole is cytotoxic in rats hepatocyte .
|
-
- HY-119635
-
|
|
Others
|
Cancer
|
|
Albicanol is a sesquiterpenoid with potent antioxidant and antagonistic activities against heavy metal toxicity. Albicanol shows cytotoxicity. Albicanol suppress profenofos (HY-B0832) induced genotoxicity in grass carp hepatocytes .
|
-
- HY-P1415A
-
-
- HY-161993
-
|
|
Ketohexokinase
|
Metabolic Disease
|
|
BI-9787 is a zwitterionic inhibitior for ketohexokinase, with an IC50 of 12 and 12.8 nM for hKHK-A and hKHK-C. BI-9787 exhibits good metabolic stability in rat hepatocyte and good pharmacokinetic characteristics in rats .
|
-
- HY-N13159
-
|
|
Others
|
Inflammation/Immunology
|
|
Goodyeroside A is a glycoside compound derived from the plant Goodyera that exhibits significant hepatoprotective activity. It can inhibit liver damage induced by carbon tetrachloride (HY-Y0298) in primary cultured rat hepatocytes .
|
-
- HY-105912
-
|
|
Others
|
Endocrinology
|
|
ONO 1082 is a Prostaglandin E1 (PGE1) (HY-B0131) derivative and increases cAMP level in hepatocytes. ONO 1082 competes with the action of the cholestatic factor through the increase in the cAMP level .
|
-
- HY-B0208
-
|
Thiamazole
|
Others
|
Endocrinology
|
|
Methimazole is an antithyroid compound widely used for the research of hyperthyroidism. Methimazole has potent hepatotoxicity .
|
-
- HY-B0208R
-
|
|
Others
|
Endocrinology
|
|
Methimazole (Standard) is the analytical standard of Methimazole. This product is intended for research and analytical applications. Methimazole is an antithyroid compound widely used for the research of hyperthyroidism. Methimazole has potent hepatotoxicity .
|
-
- HY-162854
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
Diacylglycerol acyltransferase inhibitor-2 (Example 8) is an inhibitor of Diacylglycerol Acyl Transferase 2 (DGAT2) with an IC50 value of 3.7 nM .
|
-
- HY-15880
-
|
|
Phosphatase
Apoptosis
Autophagy
|
Cancer
|
|
CCT007093 is an effective protein phosphatase 1D (PPM1D Wip1) inhibitor. Wip1 inhibition can activate the mTORC1 pathway and enhance hepatocyte proliferation after hepatectomy .
|
-
- HY-148803
-
|
|
c-Met/HGFR
|
Cancer
|
|
Vabametkib is a potent inhibitor of hepatocyte growth factor receptor (HGFR). Vabametkib inhibits Hs746T cells proliferation and inhibits c-Met with an IC50 value of 7 nM. Vabametkib can be used as an antineoplastic agent .
|
-
- HY-N6073
-
|
|
Apoptosis
|
Inflammation/Immunology
|
|
Soyasapogenol A, a triterpene compound, isolated from soybean. Soyasapogenol A directly prevents apoptosis of hepatocytes, and secondly, inhibits the elevation of plasma TNF-α, which consequently results in the prevention of liver damage in the Concanavalin A-induced hepatitis model .
|
-
- HY-148610
-
|
|
Others
|
Metabolic Disease
|
|
LDH-IN-2, a salicylic acid derivative, is an inhibitor of glycolate oxidase (GO). LDH-IN-2 decreases oxalate output in hyperoxaluric hepatocytes. LDH-IN-2 can be used for research of primary hyperoxaluria type 1 (PH1) .
|
-
- HY-132603A
-
|
|
HBV
Small Interfering RNA (siRNA)
|
Infection
|
|
AB-729 sodium is a siRNA specifically designed to inhibit viral replication and reduces HBV antigens . AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR).
|
-
- HY-130587
-
|
Piperazine sultosylate; A-585
|
Others
|
Metabolic Disease
|
|
Sultosilic acid piperazine salt (Piperazine sultosylate; A-585) is a lipid-lowering agent. Sultosilic acid piperazine salt modifies the blood lipids levels, reduces platelet adhesiveness without promoting peroxisomal activity of hepatocytes or producing other adverse side-effects .
|
-
- HY-103243
-
TCPOBOP
3 Publications Verification
|
Bcl-2 Family
|
Cancer
|
|
TCPOBOP is a constitutive androstane receptor (CAR) agonist that induces robust hepatocyte proliferation and hepatomegaly without any liver injury or tissue loss . TCPOBOP attenuates Fas-induced murine liver injury by altering Bcl-2 proteins .
|
-
- HY-N2334AS
-
|
Chenodeoxycholylglycine-d7 (sodium); Sodium glycochenodeoxycholate-d7
|
Endogenous Metabolite
Apoptosis
|
Cancer
|
|
Glycochenodeoxycholic acid-d7 (sodium) is the deuterium labeled Glycochenodeoxycholic acid (sodium salt). Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) induces hepatocyte apoptosis[1][2].
|
-
- HY-N2078
-
|
Neodiosgenin
|
LXR
|
Metabolic Disease
|
|
Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin (Neodiosgenin) inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes .
|
-
- HY-N2334S
-
|
Chenodeoxycholylglycine-d4
|
Isotope-Labeled Compounds
Endogenous Metabolite
Apoptosis
|
Cancer
|
|
Glycochenodeoxycholic acid-d4 is the deuterium labeled Glycochenodeoxycholic acid. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) induces hepatocyte apoptosis[1][2].
|
-
- HY-149055
-
|
|
CXCR
|
Inflammation/Immunology
|
|
ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11 .
|
-
- HY-125731R
-
|
|
Endogenous Metabolite
STAT
Autophagy
|
Inflammation/Immunology
Cancer
|
|
Glycodeoxycholic Acid (Standard) is the analytical standard of Glycodeoxycholic Acid. This product is intended for research and analytical applications. Glycodeoxycholic Acid is a natural product found in Streptomyces nigricans, Trypanosoma brucei and C. elegans. Glycodeoxycholic Acid induces hepatocyte necrosis and autophagy in patients with obstructive cholestasis .
|
-
- HY-101491
-
SR-18292
Maximum Cited Publications
43 Publications Verification
|
PGC-1α
Autophagy
|
Metabolic Disease
|
|
SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.
|
-
- HY-N6638R
-
|
|
Others
|
Metabolic Disease
|
|
Retrorsine (Standard) is the analytical standard of Retrorsine. This product is intended for research and analytical applications. Retrorsine is a naturally occurring toxic pyrrolizidine alkaloid. Retrorsine can bind with DNA and inhibits the proliferative capacity of hepatocytes. Retrorsine can be used for the research of hepatocellular injury .
|
-
- HY-B0544
-
|
Sodium Picosulphate
|
Others
|
Metabolic Disease
|
|
Sodium Picosulfate (Sodium Picosulphate) is a contact irritant laxative with oral activity. Sodium Picosulfate inhibits the absorption of water and electrolytes, increasing their production. Sodium Picosulfate can be used in colonoscopy applications .
|
-
- HY-120940
-
|
|
PAK
|
Cancer
|
|
AZ13705339 is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 can be used in the research of cancers .
|
-
- HY-118339
-
|
|
5-HT Receptor
|
Cancer
|
|
PF-4479745 is a potent and selective 5-HT2C receptor agonist (EC50: 10 nM, ki: 15 nM). PF-4479745 can be used in the research of cardiovascular disease like hypertension .
|
-
- HY-150052
-
|
|
Kallikrein
|
Cardiovascular Disease
Metabolic Disease
|
|
Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
|
-
- HY-120940A
-
|
|
PAK
|
Cancer
|
|
AZ13705339 hemihydrate is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 hemihydrate has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 hemihydrate can be used in the research of cancers .
|
-
- HY-107793
-
|
|
Others
|
Metabolic Disease
|
|
Picosulfate sodium salt hydrate is the hydrate of Sodium Picosulfate (HY-B0544). Picosulfate sodium salt hydrate is an orally active contact irritant laxative. Picosulfate sodium salt hydrate inhibits the absorption of water and electrolytes, increasing their production. Picosulfate sodium salt hydrate can be used in colonoscopy applications .
|
-
- HY-129333
-
|
|
Oxytocin Receptor
Vasopressin Receptor
|
Metabolic Disease
|
|
L-364918 is a potent and selective oxytocin and arginine vasopressin antagonist with Ki values of 30, 1300, 2400 nM for OT, AVP-V1, AVP-V2, respectively. L-364918 has the potential for the research of preterm labor and disturbances in water balance .
|
-
- HY-B0544R
-
|
Sodium Picosulphate (Standard)
|
Others
|
Metabolic Disease
|
|
Sodium Picosulfate (Standard) is the analytical standard of Sodium Picosulfate. This product is intended for research and analytical applications. Sodium Picosulfate inhibits the absorption of water and electrolytes and increases their secretion.
|
-
- HY-128029
-
|
|
Others
|
Metabolic Disease
|
|
Glycogen phosphorylase-IN-1 (Compound 42) is an inhibitor for human liver glycogen phosphorylase (hlGPa) and hepatocyte glycogen-derived glucose production with IC50s of 53 and 380 nM, respectively. Glycogen phosphorylase-IN-1 reveals efficacy towards type 2 diabetes .
|
-
- HY-163702
-
|
|
Adrenergic Receptor
mAChR
|
Inflammation/Immunology
|
|
CHF-6550 is an antagonist for muscarinic M3 receptor and an agonist for β2 adrenoceptor (MABA), with pKi of 9.3 and 10.6, respectively. CHF-6550 exhibits good hepatocyte clearance in rat models and good pharmacokinetic characteristics in guinea pigs .
|
-
- HY-P3465
-
|
Myrcludex B
|
HBV
|
Infection
|
|
Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research .
|
-
- HY-W104819
-
|
4-Hydroxyphenylglyoxylic acid; 4-HPGA
|
Others
|
Metabolic Disease
|
|
4-Hydroxyphenylglyoxylate (4-Hydroxyphenylglyoxylic acid) is an inhibitor of carnitine palmitoyltransferase I (CPT I). 4-Hydroxyphenylglyoxylate can be used to study sensitivity changes in CPT I of liver mitochondria and fatty acid oxidation by isolated hepatocytes. 4-Hydroxyphenylglyoxylate can inhibits fatty acid oxidation .
|
-
- HY-145855
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
J-1063 is a potent, selective and orally active ALK5 inhibitor with an IC50 of 0.039 µM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis .
|
-
- HY-163131
-
|
|
Glucosylceramide Synthase (GCS)
|
Neurological Disease
|
|
Glucosylceramide synthase-IN-4 (compound 12) is a potent glucosylceramide synthase (GCS) inhibitor, with an IC50 of 6.8 nM. Glucosylceramide synthase-IN-4 shows excellent PK properties and stability in human hepatocytes. Glucosylceramide synthase-IN-4 has good CNS penetration and acceptable PXR selectivity .
|
-
- HY-113820
-
|
|
PPAR
|
Metabolic Disease
|
|
AZD4619 is an orally active, selective peroxisome proliferator-activated receptor α (PPARα) agonist. AZD4619 increases alanine aminotransferase 1 (ALT1) protein expression in a dose-dependent manner in human, but not in rat primary hepatocytes. AZD4619 is a lipid-lowering drug .
|
-
- HY-145713
-
|
HBV-IN-19
|
HBV
|
Infection
|
|
GS-8873 is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 causes neurofunctional deficits in rats and cynomolgus monkeys .
|
-
- HY-119971
-
|
|
Others
|
Metabolic Disease
Cancer
|
|
BIM5078 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BIM5078 represses insulin promoter activity through HNF4α antagonism. BIM5078 can be used for the research of cancer and diabetes .
|
-
- HY-157976
-
|
dinor-PGE1
|
Endogenous Metabolite
Prostaglandin Receptor
|
Others
|
|
Dinorprostaglandin E1 (dinor-PGE1) is the hepatocyte metabolite of prostaglandin E1 and prostaglandin E. Prostaglandin E1 and prostaglandin E inhibit glucagon, epinephrine, isoproterenol (beta-adrenergic agonist), or epinephrine-stimulated glycogenolysis when co-treated with Isoproterenol (HY-B0468) .
|
-
- HY-117985A
-
|
DA-1229 hydrochloride
|
Dipeptidyl Peptidase
|
Metabolic Disease
Endocrinology
|
|
Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
|
-
- HY-N4323R
-
|
|
Calcium Channel
|
Neurological Disease
Metabolic Disease
|
|
14-Deoxyandrographolide (Standard) is the analytical standard of 14-Deoxyandrographolide. This product is intended for research and analytical applications. 14-Deoxyandrographolide is a labdane diterpene with calcium channel blocking activity. 14-Deoxyandrographolide desensitizes hepatocytes to TNF-α-mediated apoptosis through the release of TNFRSF1A release .
|
-
- HY-B0978
-
|
DEET; N,N-Diethyl-m-toluamide
|
Parasite
|
Infection
Neurological Disease
|
|
Diethyltoluamide (DEET) is the most common active ingredient in insect repellents. It is intended to provide protection against mosquitoes, ticks, fleas, chiggers, leeches, and many other biting insects. Diethyltoluamide is toxic to hepatocytes and can lead to many physiological, pharmacological, and behavioral abnormalities, particularly motor deficits and learning and memory dysfunction .
|
-
- HY-120103
-
|
|
Sodium Channel
|
Metabolic Disease
|
|
PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC50 value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism .
|
-
- HY-P2911
-
|
GLDH
|
Mitochondrial Metabolism
|
Others
|
|
Glutamate dehydrogenase NAD(P) (GLDH) can be found in hepatocytes, renal tissue, brain, muscle, and intestinal cells. Glutamate dehydrogenase NAD(P) is often used in biochemical studies. Glutamate dehydrogenase is a mitochondrial enzyme, it catalyzes the reversible oxidative deamination of glutamate to α-ketoglutarate (α-KG) as part of the urea cycle .
|
-
- HY-N6073R
-
|
|
Apoptosis
|
Inflammation/Immunology
|
|
Soyasapogenol A (Standard) is the analytical standard of Soyasapogenol A. This product is intended for research and analytical applications. Soyasapogenol A, a triterpene compound, isolated from soybean. Soyasapogenol A directly prevents apoptosis of hepatocytes, and secondly, inhibits the elevation of plasma TNF-α, which consequently results in the prevention of liver damage in the Concanavalin A-induced hepatitis model .
|
-
- HY-N2078R
-
|
|
LXR
|
Metabolic Disease
|
|
Yamogenin (Standard) is the analytical standard of Yamogenin. This product is intended for research and analytical applications. Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin (Neodiosgenin) inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes .
|
-
- HY-124542
-
|
|
Drug Metabolite
Apoptosis
|
Cancer
|
|
5-Hydroxydiclofenac is a major metabolite of Diclofenac (HY-15036). 5-Hydroxydiclofenac is formed by the cytochrome P450 (CYP) isoforms CYP3A4, CYP2C189, CYP2C19, and CYP2C8. 5-Hydroxydiclofenac shows apoptotic effects in hepatocytes .
|
-
- HY-128075
-
|
|
Others
|
Cancer
|
|
Acifluorfen, a protoporphyrinogen oxidase (PROTOX) inhibitor herbicide, promotes the accumulation of protoporphyrin IX (PPIX), and induces tumors in the rodent liver. Acifluorfen causes strong photooxidative destruction of pigments and lipids in sensitive plant species .
|
-
- HY-133707
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .
|
-
- HY-P4685
-
|
|
Angiotensin Receptor
|
Metabolic Disease
|
|
(Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .
|
-
- HY-128075R
-
|
|
Others
|
Cancer
|
|
Acifluorfen (Standard) is the analytical standard of Acifluorfen. This product is intended for research and analytical applications. Acifluorfen, a protoporphyrinogen oxidase (PROTOX) inhibitor herbicide, promotes the accumulation of protoporphyrin IX (PPIX), and induces tumors in the rodent liver. Acifluorfen causes strong photooxidative destruction of pigments and lipids in sensitive plant species .
|
-
- HY-118985
-
|
|
Others
|
Cancer
|
|
Acifluorfen sodium, a protoporphyrinogen oxidase (PROTOX) inhibitor herbicide, promotes the accumulation of protoporphyrin IX (PPIX), and induces tumors in the rodent liver. Acifluorfen sodium causes strong photooxidative destruction of pigments and lipids in sensitive plant species .
|
-
- HY-118386
-
|
|
Others
|
Metabolic Disease
|
|
H2-005 is a compound that selectively inhibits diacylglycerol acyltransferase 2 (DGAT2) and has the activity to inhibit triacylglycerol synthesis in hepatocytes and preadipocytes. H2-005 significantly reduces triacylglycerol biosynthesis in HepG2 hepatocytes and 3T3-L1 preadipocytes. H2-005 exhibits specific inhibitory activity in DGAT2-overexpressing HEK293 cells. H2-005 almost completely inhibits lipid droplet formation in 3T3-L1 cells when co-treated with a DGAT1 inhibitor. H2-005 will contribute to DGAT2-related lipid metabolism research and the development of drugs to inhibit metabolic diseases .
|
-
- HY-A0060
-
|
NKK 105
|
Lipoxygenase
|
Cancer
|
|
Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes .
|
-
- HY-10545
-
|
|
HBV
HCV
|
Infection
|
|
Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin, is a ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia .
|
-
- HY-10545A
-
|
|
HBV
HCV
|
Infection
|
|
Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia .
|
-
- HY-B0144AS1
-
|
NK-104-d5 sodium
|
Apoptosis
HMG-CoA Reductase (HMGCR)
Mitophagy
Autophagy
|
Metabolic Disease
Cancer
|
|
Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
|
-
- HY-157416
-
|
|
Others
|
Metabolic Disease
|
|
COP1-ATGL modulator 1 (86) is an orally active modulator for COP1-ATGL axis. COP1-ATGL modulator 1 (86) could increase ATGL protein expression, reduce ATGL ubiquitination and COP1 autoubiquitination, and diminish lipid accumulation in hepatocytes in the nanomolar range .
|
-
- HY-148476
-
|
|
LYTACs
|
Others
|
|
Tri-GalNAc-DBCO can bind to the desialic acid glycoprotein receptor (ASGPR) to drive protein downregulation and target protein degradation, where GalNAc is a high-affinity ligand for hepatocyte-specific ASGPR . Tri-GalNAc-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-163324A
-
|
|
Cytochrome P450
|
Others
|
|
2-Me PeER is a rhodamine dye-based fluorescent probe that detects CYP3A4 activity. In fluorescence-activated cell sorting (FACS) based on CYP3A4 activity, homogeneous and functional human induced pluripotent stem cell (hiPSC)-derived hepatocytes and intestinal epithelial cells can be obtained with the aid of 2-Me PeER .
|
-
- HY-18056
-
|
|
Others
|
Metabolic Disease
|
|
PF-915275 is a potent, selective and orally active human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) inhibitor with a Ki of 2.3 nM and an EC50 of 15 nM (in HEK293 cells). The dose-dependent effect of PF-915275 on conversion of cortisone to cortisol in primary human and monkey hepatocytes, with an EC50 of 20 and 100 nM, respectively .
|
-
- HY-12564
-
|
|
Aurora Kinase
Apoptosis
|
Cancer
|
|
Phthalazinone pyrazole is a potent, selective, and orally active inhibitor of Aurora-A kinase with an IC50 of 0.031 μM. Phthalazinone pyrazole can arrests mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells. Phthalazinone pyrazole suppresses the epithelial-mesenchymal transition (EMT) during the differentiation of hepatocyte-like cells (HLCs) from human embryonic stem cells .
|
-
- HY-P4672
-
|
|
GCGR
|
Metabolic Disease
|
|
(Met(O)27)-Glucagon (1-29) (human, rat, porcine) is a modified glucagon. (Met(O)27)-Glucagon (1-29) (human, rat, porcine) has the same maximum glucose-synthesizing activity in rat hepatocytes as native glucagon, but it is less potent, suggesting a crucial role of methionine in the binding of glucagon to its hepatic receptor .
|
-
- HY-155539
-
|
|
Others
|
Inflammation/Immunology
|
|
Cisd2 agonist 2 (compound 6) is an orally active Cisd2 activator (EC50=191 nM), while the Cisd2 levels is correlated with nonalcoholic fatty liver disease (NAFLD). Cisd2 agonist 2 has no significant toxicity in vivo in Cisd2hKO-het mice (heterozygous hepatocyte-specific Cisd2 knockout) .
|
-
- HY-162738
-
|
|
Cytochrome P450
|
Cancer
|
|
JMV6944 is a PXR agonist. JMV6944 competitively inhibits hPXR ligand-binding domain (LBD) binding to PXR with an IC50 of 680nM. JMV6944 induces CYP3A4 mRNA expression in freshly isolated human primary human hepatocyte cultures. JMV6944 can be used for the synthesis of PROTAC PXR degrader JMV7048 (HY-162704) .
|
-
- HY-155108
-
|
|
Arginase
|
Cancer
|
|
OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study .
|
-
- HY-161247
-
|
|
5-HT Receptor
|
Metabolic Disease
|
|
5HT2A antagonist 2 is an orally active, selective antagonist for 5HT2A with IC50 of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .
|
-
- HY-158160
-
|
|
Sodium Channel
|
Metabolic Disease
|
|
LBA-3 is a selective, orally active inhibitor for sodium-coupled citrate transporter SLC13A5, with an IC50 of 67 nM. LBA-3 decreases levels of triglyceride and total cholesterol in oleic and palmitic acid (OPA)-stimulated AML12 cells, PCN-stimulated primary mouse hepatocytes and in mouse models, without detectable toxicity. LBA-3 is blood-brain barrier permeable .
|
-
- HY-114363A
-
|
|
c-Met/HGFR
|
Cancer
|
|
SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer .
|
-
- HY-120657
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
|
|
9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .
|
-
- HY-15424
-
|
NSC 113939; 5-ITu
|
Adenosine Kinase
|
Cancer
|
|
5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .
|
-
- HY-B0144A
-
|
NK-104
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
- HY-116282D
-
|
DSS (MW 450000-550000); DXS (MW 450000-550000)
|
HIV
Apoptosis
|
Others
|
|
Dextran sulfate sodium salt (MW 450000-550000) is a polymer of anhydroglucose with a molecular weight range of 450000-550000. Dextran sulfate sodium salt (MW 450000-550000) can effectively enrich precipitated cells and can be used to isolate neutrophils from human and rat blood. Dextran sulfate sodium salt (average MW 500000) can effectively enhance the conversion activity of coagulation factor XIIa (FXIIa) to induce hepatocyte growth factor (HGF) and increase the specific activity of FXIIa.
|
-
- HY-B0144B
-
|
NK-104 sodium
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
- HY-143260
-
|
|
GSK-3
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
GSK-3β inhibitor 6 is a potent GSK-3β inhibitor with an IC50 value of 24.4 μM. GSK-3β inhibitor 6 shows high hepatocyte glucose uptake (38%). GSK-3β inhibitor 6 can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .
|
-
- HY-14391
-
|
GS-558093
|
HCV
|
Infection
|
|
PSI-353661 (GS-558093) is a purine nucleotide NS5B polymerase inhibitor against HCV infection. PSI-353661 shows EC90s of 8 nM and 11 nM for wild type and S282T resistant replicons of HCV. PSI-353661 can produce high concentrations of the active triphosphate in primary human hepatocytes .
|
-
- HY-16969
-
Dihexa
5 Publications Verification
PNB-0408; N-hexanoic-Try-Ile-(6)-amino hexanoic amide; Hexanoyl-Tyr-Ile-Ahx-NH2
|
c-Met/HGFR
|
Neurological Disease
|
|
Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds to hepatocyte growth factor (HGF) with high affinity (Kd=65 pM) and potentiates its activity at its receptor, c-Met. Dihexa exhibits excellent antidementia activity and improves cognitive function in animal models. Dihexa may have therapeutic potential as a treatment Alzheimer’s disease .
|
-
- HY-129431
-
|
|
Others
|
Others
|
|
U-89843A is a precursor of U-97924 and forms U-97924 as the major metabolite. Although U-97924 showed mutagenic potential in rat hepatocytes in a serum-free in vitro assay, no genotoxicity of U-97924 was observed in rats at high oral doses. Rat serum also inhibited the in vitro metabolism of U-89843 and the formation of the corresponding hydroxylated metabolite, U-97924 .
|
-
- HY-W587530
-
|
6-Ketolithocholic acid
|
Endogenous Metabolite
Apoptosis
|
Endocrinology
|
|
6-Oxolithocholic acid is a bile acid metabolite derived from Lithocholic acid (HY-B0172). 6-Oxolithocholic acid has high cytotoxicity and can induce apoptosis, especially in hepatocytes. 6-Oxolithocholic acid can participate in the regulation of bile acid metabolism and synthesis and affect the metabolic pathway of cholesterol. 6-Oxolithocholic acid can be used to study the role of bile acids in health and disease, especially in the context of digestive and liver diseases .
|
-
- HY-146111
-
|
|
IRAK
|
Cancer
|
|
IRAK4-IN-13 (compound 21) is a potent and selective IRAK4 inhibitor with an IC50 of 0.6 nM. IRAK4-IN-13 shows high metabolic clearance with human liver microsomes (HLM) intrinsic clearance is 96 µL/min/mg .
|
-
- HY-111179
-
|
|
Others
|
Inflammation/Immunology
|
|
ML261 is a hepatic lipid droplets formation inhibitor with an IC50 value of 69.7 nM. ML261 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and inflammation .
|
-
- HY-16219
-
|
Gd-EOB-DTPA disodium; ZK 139834
|
Biochemical Assay Reagents
|
Cancer
|
|
Gadoxetate (Gd-EOB-DTPA) Disodium is a contrast agent in magnetic resonance imaging (MRI) of the hepatobiliary system, which accumulates in normal, functioning hepatocytes. Gadoxetate Disodium aggravates liver fibrosis (LF) induced gadolinium deposition in the liver and deep cerebellar nuclei (DCN) of rats without significant acute histological alterations. Gadoxetate Disodium is used to evaluate focal liver lesions, such as hepatocellular carcinoma or dysplastic nodules .
|
-
- HY-125390
-
|
CL-087
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response . SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity .
|
-
- HY-145713A
-
|
HBV-IN-19 TFA
|
HBV
|
Infection
|
|
GS-8873 TFA is the TFA salt form of GS-8873 (HY-145713). GS-8873 TFA is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 TFA exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 TFA causes neurofunctional deficits in rats and cynomolgus monkeys .
|
-
- HY-P2185
-
|
|
MMP
|
Others
|
|
NFF-3, the peptide, is a selective MMP substrate. NFF-3 selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
|
-
- HY-W740572
-
|
|
Others
|
Inflammation/Immunology
|
|
O-Desmethyl-N-deschlorobenzoyl indomethacin is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor indomethacin (HY-14397). It is formed from indomethacin in isolated rabbit hepatocytes. O-Desmethyl-N-deschlorobenzoyl indomethacin (600 μM) decreases the viability of HL-60 leukemia cells when cultured with glucose oxidase. It has also been used in the synthesis of prostaglandin D2 (HY-101988) receptor antagonists.
|
-
- HY-B0144S
-
|
NK-104-d4 hemicalcium; Pitavastatin-d4 hemicalcium
|
Isotope-Labeled Compounds
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Metabolic Disease
Cancer
|
|
Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
|
-
- HY-P2185A
-
|
|
MMP
|
Others
|
|
NFF-3 TFA, the peptide, is a selective MMP substrate. NFF-3 TFA selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 TFA is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 TFA with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
|
-
- HY-B0766
-
|
SY801
|
Autophagy
Apoptosis
HBV
HCV
HSP
Reactive Oxygen Species
Bcl-2 Family
Glutathione S-transferase
p38 MAPK
NF-κB
Microtubule/Tubulin
ERK
JNK
TNF Receptor
Interleukin Related
CDK
Cyclin G-associated Kinase (GAK)
mTOR
P-glycoprotein
Ferroptosis
|
Infection
Inflammation/Immunology
Cancer
|
|
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .
|
-
- HY-B0144
-
|
NK-104 hemicalcium; Pitavastatin hemicalcium
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
- HY-N2334
-
|
Chenodeoxycholylglycine
|
Endogenous Metabolite
Apoptosis
STAT
BCL6
Interleukin Related
Caspase
|
Metabolic Disease
Cancer
|
|
Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .
|
-
- HY-W012974
-
|
β-Aminoisobutyric acid; BAIBA
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
3-Aminoisobutyric acid (β-Aminoisobutyric acid) has anti-inflammatory and antioxidant effects. 3-Aminoisobutyric acid increases the expression of brown adipocyte-specific genes in white adipose tissue and fatty acid β-oxidation in hepatocytes. 3-Aminoisobutyric acid attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK–PPARδ-dependent pathway in mice. 3-Aminoisobutyric acid is a catabolic metabolite of thymine and valine in skeletal muscle .
|
-
- HY-N2334A
-
|
Chenodeoxycholylglycine sodium salt; Sodium glycochenodeoxycholate
|
Endogenous Metabolite
Apoptosis
STAT
BCL6
Interleukin Related
Caspase
|
Metabolic Disease
Cancer
|
|
Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .
|
-
- HY-165098
-
|
β-Aminoisobutyric acid sodium salt; BAIBA sodium salt
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
3-Aminoisobutyric acid (β-Aminoisobutyric acid) sodium salt has anti-inflammatory and antioxidant effects. 3-Aminoisobutyric acid sodium salt increases the expression of brown adipocyte-specific genes in white adipose tissue and fatty acid β-oxidation in hepatocytes. 3-Aminoisobutyric acid sodium salt attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK–PPARδ-dependent pathway in mice. 3-Aminoisobutyric acid sodium salt is a catabolic metabolite of thymine and valine in skeletal muscle .
|
-
- HY-118932
-
|
|
HCV
|
Infection
|
|
HCV-IN-45 (Compound EI-1) is an inhibitor for hepatitis C virus (HCV), that inhibits 1a and 1b HCV pseudoparticles with EC50 of 0.134 and 0.027 μM. HCV-IN-45 inhibits 1a/2a and 1b/2a cell culture-adapted HCV (HCVcc), with EC50 of 0.024 and 0.012μM. HCV-IN-45 inhibits the entry of the virus into hepatocyte, and blocks the cell-cell spread .
|
-
- HY-10338A
-
|
|
VEGFR
Others
c-Met/HGFR
|
Cancer
|
|
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .
|
-
- HY-143261
-
|
|
GSK-3
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
GSK-3β inhibitor 7 is a GSK-3β inhibitor with an IC50 value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .
|
-
- HY-19109
-
|
|
Others
|
Others
|
|
RG-7152 is a tetrazolyl-substituted leukotriene D4 receptor antagonist that can induce peroxisomal β-oxidation and peroxisome bifunctional enzymes (PBEs) in hepatocytes in various animal models. It has been shown to significantly increase PBE levels and β-oxidation activity in rat and mouse liver homogenates, while smaller effects were observed in guinea pigs and monkeys and no effect in dogs. In vitro studies have also shown that it can induce PBEs comparable to clofibric acid, indicating its potential as a peroxisome proliferator .
|
-
- HY-B1727
-
|
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Phenanthrene is an orally active polycyclic aromatic hydrocarbon (PAH) that induces inflammation, oxidative stress, and apoptosis. Additionally, phenanthrene is commonly used to detect or assess PAH pollution in the environment .
|
-
- HY-142114
-
|
|
Others
|
Metabolic Disease
|
|
SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes .
|
-
- HY-122812
-
|
|
Others
|
Others
|
|
Maesopsin is a phenolic compound, that can be isolated from Hoveniae Lignum .
|
-
- HY-162584
-
|
|
TRP Channel
|
Others
|
|
TRPC4/5-IN-2 (Compound 12) is an orally effective transient receptor potential (TRPC5) inhibitor with a IC50 value of 81 nM. TRPC4/5-IN-2 has good biosafety and low liver and kidney toxicity, and is expected to play an important role in the treatment of chronic kidney disease (CKD) .
|
-
- HY-B1727R
-
|
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Phenanthrene (Standard) is the analytical standard of Phenanthrene. This product is intended for research and analytical applications. Phenanthrene is an orally active polycyclic aromatic hydrocarbon (PAH) that induces inflammation, oxidative stress, and apoptosis. Additionally, phenanthrene is commonly used to detect or assess PAH pollution in the environment .
|
-
- HY-160023
-
|
|
Ras
|
Cancer
|
|
D3S-001 is an orally active inhibitor for KRAS. D3S-001 inhibits the proliferation of KRAS G12C mutant H358 and MIA-PA-CA-2 with an IC50 of 0.6 and 0.44 nM. D3S-001 exhibits good metabolic stability in hepatocytes, liver microsomes, plasma and whole blood in various species. D3S-001 exhibits good pharmacokinetic characteristics and antitumor efficacy in mice .
|
-
- HY-B0822R
-
|
|
GABA Receptor
Cytochrome P450
Apoptosis
|
Neurological Disease
|
|
Fipronil (Standard) is the analytical standard of Fipronil. This product is intended for research and analytical applications. Fipronil is a broad-spectrum insecticide effective against Lepidoptera species as well as thrips, locusts, ants, cockroaches, fleas and ticks. Fipronil selectively inhibits GABA receptor with IC50s of 30 nM and 1600 nM for cockroach and rat GABA receptors, respectively. Glutamate-gated chloride channels (GluCls), which are present in cockroaches but not in mammals, are sensitive to the blocking effect of Fipronil. Fipronil also induces apoptosis in HepG2 cells and promotes the expression of CYP1A1 and CYP3A4 mRNA in human hepatocytes .
|
-
- HY-B0144R
-
|
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Pitavastatin (Calcium) (Standard) is the analytical standard of Pitavastatin (Calcium). This product is intended for research and analytical applications. Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
- HY-120270
-
|
|
AMPK
|
Metabolic Disease
|
|
PF-06679142 (Compound 10) is a potent, orally active AMPK activator with an EC50 of 22 nM against α1β1γ1-AMPK. PF-06679142 can be used for diabetic nephropathy research .
|
-
- HY-121132
-
|
|
Others
|
Inflammation/Immunology
|
|
Butibufen is an orally active non-steroidal compound. Butibufen shows analgesic and antipyretic properties. Butibufen can be used for the research of inflammation .
|
-
- HY-155108B
-
|
|
Arginase
|
Cancer
|
|
OATD-02 hydrochloride is the hydrochloride salt form of OATD-02 (HY-155108). OATD-02 hydrochloride an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and Arginase2. OATD-02 hydrochloride is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 hydrochloride bolishes tumor immunosuppression induced by both arginases. OATD-02 hydrochloride can be used for melanoma study .
|
-
- HY-15042
-
|
|
Bradykinin Receptor
|
Metabolic Disease
|
|
MK 0686, a potent bradykinin B1 receptor antagonist, demonstrates autoinduction of metabolism in rhesus monkeys after oral administration. It undergoes significant biotransformation primarily via oxidation pathways, leading to the formation of metabolites like M11 and M13 in rhesus liver microsomes. This metabolic induction is mediated by CYP2C75, as evidenced by increased mRNA expression, protein levels, and catalytic activity of this enzyme in hepatocytes and liver microsomes from MK 0686-treated animals. The autoinduction phenomenon suggests that MK 0686 enhances its own metabolism by upregulating CYP2C75, potentially influencing its systemic exposure and pharmacokinetics over time .
|
-
- HY-114294A
-
|
HMG-CoA disodium hydrate
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium hydrate is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor .
|
-
- HY-148781
-
|
|
HBV
|
Infection
|
|
HBV-IN-30 (ex44), a flavone derivative, is a potent covalently closed circular DNA (cccDNA) inhibitor. cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-30 has the potential for the research of HBV infection .
|
-
- HY-148780
-
|
|
HBV
|
Infection
|
|
HBV-IN-29 (ex8), a flavone derivative, is a potent covalently closed circular DNA (cccDNA) inhibitor. cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-29 has the potential for the research of HBV infection .
|
-
- HY-154855
-
|
|
HDAC
|
Cancer
|
|
HDAC-IN-56 ((S)-17b) is an orally active class I histone deacetylase (HDAC) inhibitor with IC50 values of 56.0 ± 6.0, 90.0 ± 5.9, 422.2 ± 105.1, >10000 nM for HDAC1, HDAC2, HDAC3, and HDAC4-11, respectively. HDAC-IN-56 has potent inhibitory activity while strongly increasing intracellular levels of acetylhistone H3 and P21 and effectively inducing G1 cell cycle arrest and apoptosis.HDAC-IN-56 has antitumor activity .
|
-
- HY-N2896
-
|
|
Reactive Oxygen Species
|
Inflammation/Immunology
|
|
Arjunolic acid is a saponin isolated from Cyclocarya paliurus and has various biologial activities, including antioxidant, antimicrobial, antibacterial and anti-inflammory activities. Arjunolic acid is also a potent antioxidant and plays an important role in the protection of cells and tissues against deleterious effects of reactive oxygen species .
|
-
- HY-19543
-
|
NSC 172924
|
Keap1-Nrf2
Apoptosis
|
Cancer
|
|
Brusatol (NSC 172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent . Brusatol increases cellular apoptosis .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-P2185
-
|
|
Dyes
|
|
NFF-3, the peptide, is a selective MMP substrate. NFF-3 selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
|
| Cat. No. |
Product Name |
Type |
-
- HY-114294A
-
|
HMG-CoA disodium hydrate
|
Enzyme Substrates
|
|
DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium hydrate is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1415A
-
-
- HY-P3465
-
|
Myrcludex B
|
HBV
|
Infection
|
|
Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research .
|
-
- HY-P4685
-
|
|
Angiotensin Receptor
|
Metabolic Disease
|
|
(Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .
|
-
- HY-P2185A
-
|
|
MMP
|
Others
|
|
NFF-3 TFA, the peptide, is a selective MMP substrate. NFF-3 TFA selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 TFA is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 TFA with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
|
-
- HY-P10241
-
|
|
Apoptosis
Caspase
|
Cancer
|
|
Ac-LEHD-CHO is an inhibitor for caspase 8/9. Ac-LEHD-CHO prevents GalN/TNF-α-induced hepatotoxicity and hepatocyte apoptosis .
|
-
- HY-P4097
-
|
|
Peptides
|
Others
|
|
293P-1 is a peptide with tissue-specific homing properties. 293P-1 is specific for hepatocytes with sequences of SNNNVRPIHIWP .
|
-
- HY-P1415
-
-
- HY-P5496
-
|
|
Peptides
|
Others
|
|
AAV2 Epitope is a biological active peptide. (This peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells.)
|
-
- HY-P4672
-
|
|
GCGR
|
Metabolic Disease
|
|
(Met(O)27)-Glucagon (1-29) (human, rat, porcine) is a modified glucagon. (Met(O)27)-Glucagon (1-29) (human, rat, porcine) has the same maximum glucose-synthesizing activity in rat hepatocytes as native glucagon, but it is less potent, suggesting a crucial role of methionine in the binding of glucagon to its hepatic receptor .
|
-
- HY-P2185
-
|
|
MMP
|
Others
|
|
NFF-3, the peptide, is a selective MMP substrate. NFF-3 selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99391
-
|
ABT-700
|
Inhibitory Antibodies
|
Cancer
|
|
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity .
|
-
- HY-P99217
-
|
AMG 102
|
c-Met/HGFR
|
Cancer
|
|
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
|
-
- HY-P99196
-
|
|
c-Met/HGFR
|
Cancer
|
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N2334S
-
|
|
|
Glycochenodeoxycholic acid-d4 is the deuterium labeled Glycochenodeoxycholic acid. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) induces hepatocyte apoptosis[1][2].
|
-
-
- HY-B0144AS1
-
|
|
|
Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
|
-
-
- HY-W018392S
-
|
|
|
Mono-(2-ethylhexyl) phthalate-d4 is a deuterium labeled Mono-(2-ethylhexyl) phthalate (HY-W018392). Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-12784AS
-
|
|
|
Cycloguanil-d4 (hydrochloride) is the deuterium labeled Cycloguanil hydrochloride. Cycloguanil hydrochloride, the active metabolite of Proguanil, acts on malaria schizonts in erythrocytes and hepatocytes[1].
|
-
-
- HY-12784AS1
-
|
|
|
Cycloguanil-d6 hydrochloride is the deuterium labeled Cycloguanil hydrochloride. Cycloguanil hydrochloride, the active metabolite of Proguanil, acts on malaria schizonts in erythrocytes and hepatocytes .
|
-
-
- HY-N2334AS
-
|
|
|
Glycochenodeoxycholic acid-d7 (sodium) is the deuterium labeled Glycochenodeoxycholic acid (sodium salt). Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) induces hepatocyte apoptosis[1][2].
|
-
-
- HY-B0144S
-
|
|
|
Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-148476
-
|
|
|
DBCO
|
|
Tri-GalNAc-DBCO can bind to the desialic acid glycoprotein receptor (ASGPR) to drive protein downregulation and target protein degradation, where GalNAc is a high-affinity ligand for hepatocyte-specific ASGPR . Tri-GalNAc-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-132600A
-
|
Temavirsen sodium
|
|
Antisense Oligonucleotides
|
|
RG-101 sodium is a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that antagonises miR-122. miR-122 is an important host factor for hepatitis C virus (HCV) replication .
|
-
- HY-132604A
-
|
ARO-AAT sodium
|
|
siRNAs
|
|
Fazirsiran sodium is a second-generation RNAi agent. Fazirsiran sodium consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran sodium can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
|
-
- HY-132600
-
|
Temavirsen
|
|
Antisense Oligonucleotides
|
|
RG-101 is a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that antagonises miR-122. miR-122 is an important host factor for hepatitis C virus (HCV) replication .
|
-
- HY-132604
-
|
ARO-AAT
|
|
siRNAs
|
|
Fazirsiran (ARO-AAT) is a second-generation RNAi agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
|
-
- HY-132603A
-
|
|
|
siRNAs
|
|
AB-729 sodium is a siRNA specifically designed to inhibit viral replication and reduces HBV antigens . AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR).
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
